ERKNet

The European Rare Kidney Disease Reference Network

  

ERKNet is the European Reference Network for Rare Kidney Diseases, a consortium of 38 expert pediatric and adult nephrology centers in 12 European countries providing healthcare to more than 40,000 patients with rare disorders of the kidneys.

The ERKNet partners offer top quality multidisciplinary healthcare for a wide range of rare kidney disorders. They uniformly apply clinical guidelines and pathways according to latest medical knowledge and strictly monitor the quality and outcomes of therapy across the Network.

Supported by the EU, ERKNet offers virtual consultation services to physicians throughout Europe who need advice for challenging cases with a rare kidney disease.  

ERKNet is dedicated to improve knowledge about rare kidney diseases among patients and healthcare professionals. We disseminate disease information via this website and by multiple education and training activities.  

ERKNet actively supports clinical research to improve diagnosis and risk prediction and advance the development of new therapies for patients with rare kidney disorders.  

 

In pursuing these tasks, ERKNet closely collaborates with the corresponding expert workgroups of the European nephrology societies: 

ERKNet gratefully acknowledges the societies’ support of the Network's activitites.    




Latest News

Bardoxolone Methyl Appears to Improve Kidney Function in Patients with Alport Syndrome

Interim results from the Phase 2/3 CARDINAL trial indicate that 12 weeks of treatment with bardoxolone methyl - a drug that activates a transcription factor involved in antioxidant and anti-inflammatory responses—improves eGFR in patients with Alport syndrome. eGFR improvements were observed across patients with earlier and later stages of disease and were associated with reductions in levels of uric acid, blood urea nitrogen, and phosphorous. Seventy-three percent of the 30 patients in the study improved in terms of CKD stage, and none worsened. There were no discontinuations or serious adverse events. The findings were presented at ASN Kidney Week 2017.